Does Rexulti (brexpiprazole) have a long elimination half-life?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Yes, Rexulti (brexpiprazole) has a very long elimination half-life

Rexulti has a terminal elimination half-life of approximately 91 hours (nearly 4 days), which qualifies it as a long half-life medication that can be abruptly discontinued without requiring a downward dose titration because it will "auto-taper." 1

Pharmacokinetic Profile

The FDA label clearly establishes that after multiple once-daily administrations of Rexulti:

  • Brexpiprazole half-life: 91 hours
  • Active metabolite (DM-3411) half-life: 86 hours 1

This places brexpiprazole in the same category as other long half-life psychotropics like aripiprazole, cariprazine, fluoxetine, and vortioxetine 2.

Clinical Implications for Discontinuation

The 2026 American Society of Clinical Psychopharmacology consensus guidelines specifically identify medications with long terminal elimination half-lives (including brexpiprazole) as agents that can generally be abruptly stopped without the need for downward dose titration because they undergo natural auto-tapering as plasma levels gradually decline over weeks 2.

Important Caveats:

  • Steady-state concentrations take 10-12 days to achieve 1
  • The long half-life means drug effects (both therapeutic and adverse) persist for days to weeks after discontinuation
  • When switching from brexpiprazole to another antipsychotic, the prolonged washout period must be considered to avoid overlapping drug effects
  • Drug-drug interactions involving CYP3A4 or CYP2D6 inhibitors/inducers will significantly affect brexpiprazole levels and should be monitored when these interacting medications are started or stopped 1

Additional Pharmacokinetic Considerations

  • High protein binding: >99% bound to plasma proteins 1
  • High volume of distribution: 1.56 L/kg, indicating extensive tissue distribution 1
  • Metabolism: Primarily via CYP3A4 and CYP2D6 1
  • Bioavailability: 95% oral bioavailability 1

The exceptionally long half-life of 91 hours means that even after stopping the medication, therapeutic (and potentially adverse) effects will persist for approximately 2-3 weeks as the drug gradually clears from the system.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.